1 – 10 of 50
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
GSPT1-specific protein degradation is effective in preclinical models of chemoresistant MYCN-amplified neuroblastoma
- Contribution to journal › Article
- 2025
-
Mark
Targeted ferroptosis induction enhances chemotherapy efficacy in chemoresistant neuroblastoma
- Contribution to journal › Article
-
Mark
Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma
- Contribution to journal › Article
-
Mark
Evaluation of TRPA1 as a Therapeutic Target in MYCN-Amplified Neuroblastoma
- Contribution to journal › Article
-
Mark
Evolutionary unpredictability in cancer model systems
- Contribution to journal › Article
-
Mark
Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma
(2025) In EMBO Molecular Medicine
- Contribution to journal › Article
- 2024
-
Mark
Early evolutionary branching across spatial domains predisposes to clonal replacement under chemotherapy in neuroblastoma
- Contribution to journal › Article
- 2023
-
Mark
Patient-derived models : Advanced tools for precision medicine in neuroblastoma
- Contribution to journal › Article
-
Mark
Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
- Contribution to journal › Article
-
Mark
Breast cancer associated CD169+ macrophages possess broad immunosuppressive functions but enhance antibody secretion by activated B cells
- Contribution to journal › Article
